Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We bring together biomedical, analytical and clinical expertise to shed new light on the causes that underpin neurodegenerative diseases.

https://tinyurl.com/y8vrp4hp

Join us at the Oxford Neuroinflammation Conference 2026
https://www.ndcn.ox.ac.uk/study-with-us/continuing-professional-development/oxford-neuroinflammation-conference

 

Our research team, along with our local and international collaborators, aims to design tools for faster diagnosis, accurate prognosis, and to identify new targets for life-changing and life-saving treatments.

We are located in the Weatherall Institute for Molecular Medicine (WIMM) at the John Radcliffe Hospital. ​We collaborate closely with a wide range of scientists and clinicians and have close ties to the Broad Institute and the Karolinska Institutet.

Aims

  • Harness genetic information to facilitate the diagnosis of neurodegenerative diseases
  • Determine how environmental factors contribute to disease development and progression
  • Understand why disease presentation and prevalence varies across different ethnic populations
  • Determine whether drug efficacy, indications, and potential side effects can be predicted prior to clinical testing to help prioritise therapeutic  strategies that will likely confer the greatest benefit
  • Assess whether drugs already in use for other conditions can be repurposed to accelerate the treatment of neurodegenerative disease patients - without the need for lengthy clinical trials that can take decades factors contribute to disease development and progression

Selected publications

The spatiotemporal distribution of human pathogens in ancient Eurasia

Journal article

Sikora M. et al, (2025), Nature, 643, 1011 - 1019

Immune perturbation by the ileal microbiota in multiple sclerosis.

Journal article

Jensen LT. and Fugger L., (2025), Proc Natl Acad Sci U S A, 122

A repair pathway lost in multiple sclerosis provides a new drug opportunity.

Journal article

Jensen LT. et al, (2024), Nat Immunol, 25, 385 - 386

Ancient DNA reveals evolutionary origins of autoimmune diseases.

Journal article

Barrie W. et al, (2024), Nat Rev Immunol, 24, 85 - 86

The selection landscape and genetic legacy of ancient Eurasians.

Journal article

Irving-Pease EK. et al, (2024), Nature, 625, 312 - 320

Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations.

Journal article

Barrie W. et al, (2024), Nature, 625, 321 - 328

Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.

Journal article

Jensen LT. et al, (2023), EBioMedicine, 97

The immunology of multiple sclerosis.

Journal article

Attfield KE. et al, (2022), Nat Rev Immunol, 22, 734 - 750

Identification of early neurodegenerative pathways in progressive multiple sclerosis

Journal article

Kaufmann M. et al, (2022), Nature Neuroscience, 25, 944 - 955


FUNDERS

OAK Foundation

MRC

Aims2Cure

MS Society

affiliated external collaborators

Dr Lise Torp Jensen - Aarhus University

Dr Max Kaufmann - Clinical Research Fellow, University Medical Centre Hamburg

Dr Mihai Ancau - Neurologist and Postdoctoral Researcher, Technical Institute of Munich

Our news

Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations.

Journal article

Barrie W. et al, (2024), Nature, 625, 321 - 328